90 miljoner i utdelning till cancerforskning 2024

Genom Sveriges äldsta cancerfonder – Cancerföreningen i Stockholm och Stiftelsen Konung Gustaf V:s Jubileumsfond – stödjer vi i år forskningsprojekt inom områdena barncancer, blodcancer, bröstcancer, bukspottkörtelcancer, gallgångscancer, gynekologisk cancer, hudcancer, huvud-halscancer, levercancer, lungcancer, prostatacancer, sarkom och tarmcancer.

Dessutom finansierar vi projekt inriktade på tumörers egenskaper, epidemiologi, diagnostik och behandling såsom immunterapi och strålbehandling.

Årets utdelning främjar även utvecklingen av nya effektiva cancerbehandlingar vid Karolinska Institutet. Bland annat infrastrukturstöd till GMP cellterapilaboratorium och etableringen av ett precisionsmedicinskt provlaboratorium med expertis inom avancerad provberedning och god datapraktik.

Stödet möjliggör också flera professorstjänster och forskningstid för doktorander som är kliniskt verksamma inom cancerområdet.

Tack till alla gåvogivare som bidrar till att föra cancerforskningen framåt!

ÅRETS PROJEKTANSLAG

Följande forskare och projekt har beviljats stöd:

• Mirna Abraham-Nordling, docent – Rectal Cancer: Complications – Low Anterior Resection Syndrome and Anastomotic Leakage
• Adnane Achour, professor – Development of DARPin T cell engagers for specific targeting of tumor-associated HLA/peptide complexes
• Marie Arsenian Henriksson, professor – Targeting Cancer Metabolism for Precision Medicine in Childhood Neuroblastoma
• Annika Bergquist, professor – Primär skleroserande cholangit- en premalign sjukdom
• Niklas Björkström, professor – Towards precision diagnostics based on cytotoxic lymphocyte presence in the TME
• Johannes Blom, docent – Surgery versus Endoscopic Resection for Incompletely Removed Early Colon Cancer randomized controlled trial (The SCAR trial)
• Hanna Brauner, docent – Cutaneous lymphoma – clinical and experimental studies for better health and survival
• Petter Brodin,  professor – Systemimmunologisk analys av barn med solida tumörer – ISAC studien
• Lars Olaf Cardell, professor – Prognostic Biomarkers and Mechanistic Insights in Oral Cancer: Immune Profiling of Tumor-Draining Lymph Nodes
• Tina Dalianis, professor – Precision Monitoring and Treatment in Head and Neck Cancer: Leveraging Human Papillomav Virus (HPV) and Biomarkers for Better Patient Outcomes
• Karin Ekström Smedby, professor – Utveckling och implementering av precisionsmedicin vid maligna lymfom
• Sandra Eloranta, docent – Survival and survivorship after lymphoma and colorectal cancer to aid clinical decision making and precision medicine
• Martin Enge, docent – Ultra-sensitive and clonally resolved clinical multiomics for sarcoma
• Hanna Eriksson, docent – Strategies for improving the management and survival in cutaneous melanoma: From early detection to treatment of metastatic disease
• Marianne Farnebo, docent – Characterization of RNA-mediated DNA repair and its therapeutic potential
• Anna Forsberg, docent – SCREEning of Swedish COlons (SCREESCO) – en nationell randomiserad tarmcancerscreeningstudie
• Marike Gabrielson, docent – The POWER trial: A randomised open label phase 3 clinical trial on Personalised dose Optimisation With adjuvant tamoxifen therapy in breast cancER
• Martin Halle, docent – Rekonstruktion vid strålningsinducerad vävnadsskada – kliniska och translationella studier
• Eva Hellström Lindberg, professor – Precision medicine in myelodysplastic syndromes
• Nikolas Herold, docent – Bekämpa cytostatikaresistens vid hematologiska och solida tumörer
• Lars Holmgren, professor – Identification and validation of drugs that target invasive cancer cells
• Petter Höglund, professor – Platelet transfusion in leukemia and immune responses to platelet transfusion: clinical and experimental studies
• Helena Ikonomidis Sackey, fil. dr – Strategies to reduce seroma and arm morbidity following breast cancer surgery
• Rozbeh Jafari,  docent – Integrative Multi-Omics approaches for uncovering mechanistic insights in precision therapies for acute lymphoblastic leukemia
• Henrik Johansson, docent – Proteome precision medicine to predict response and de-escalate HER2-positive breast cancer therapy II
• Katarina Le Blanc, professor – Cured but not well: Long term fatigue and cognitive dysfunction due to synaptopathy or brain GvHD?
• Janne Lehtiö, professor – Cancer proteogenomics development for precision combination treatment selection
• Rolf Lewensohn, professor – Biomarkers and advanced modelling to personalize stereotactic body radiotherapy (SBRT) regimens in non-small cell lung cancer
• Karin Lindberg, fil. dr – Integrating stereotactic body radiation therapy in metastatic lung cancer and conquering challenging tumour locations
• Andreas Lundqvist, professor — Precision cancer immunotherapy in solid tumors
• Matthias Löhr, professor – A translational and personalised approach to improve pancreatic cancer treatment
• Anna Martling, professor – Skräddarsydd diagnostik, behandling och uppföljning av patienter med kolorektalcancer – randomiserade, observationella och epidemiologiska studier
• Håkan Mellstedt, professor – The ROR1 and fractalkine receptors as novel targets facilitating development of PrecisionCancerMedicine (PCM)
• Sten Nilsson, professor – Målspecifik behandling av tumörsjukdomar
• Ann Nordgren, professor – Molecular and Epidemiological studies of Childhood Cancer predisposition
• Joel Nordin, fil. dr – Development of in vivo generated CAR T cells resistant to lymphodepletion for translational precision medicine applications
• Lukas Orre, docent – Investigation of immune evasion mechanisms in STK11 inactivated non-small cell lung cancer
• Qiang Pan-Hammarström, professor – Clinical and genetic studies on malignant B cell lymphomas –basis for development of better prognostic models and novel therapies
• Charlotte Rolny, docent – Identifiering av nya målriktade terapier för reprogrammering av tumörfrämjande makrofager: En väg mot förbättrat immunsvar vid cancer
• Leif Stenke, professor – Modulering av aberrant cellsignalering vid kronisk myeloisk leukemi
• Fredrik Strand, docent – SmartScan: AI-Driven Precision Medicine in Breast MRI
• Staffan Strömblad, professor – Vilka pre-invasiva tumörer ska behandlas eller följas upp?
• Per Stål, professor – Förbättrad screening av levercellscancer
• Magnus Tobiasson, docent – Minimal residual disease (MRD)-targeted treatment to improve outcome of allogeneic stem cell transplantation for patients with myelodysplastic syndrom
• Nicholas Tobin, docent – Clinical Risk Tools in Older Cancer Patients – Need for Reoptimisation?
• Iuliana Toma-Dasu, professor – A testbed for proton radiotherapy – further development accounting for physical, radiobiological and clinical parameters
• Malin Wickström, docent – Novel approaches for neuroblastoma differentiation therapy
• Stina Wickström, docent – Improving cellular immunotherapy for gynecological cancers
• Oscar Wiklander, med. dr – Extracellular vesicle-based Precision Diagnostics in Cancer
• Margareta Wilhelm, docent – Identifying molecular mechanisms and therapeutic targets in childhood brain tumors
• Petter Woll, fil. dr – Image-based surveillance of therapy-resistant leukemic stem cells
• Ioannis Zerdes, fil. dr – Unveiling immunotherapy biomarkers and novel targets in early triple-negative breast cancer: a translational real-world multi-omics study
• Pia Österlund, professor – Clinical factors, mutational landscape, and tumour microenvironment of metastatic colorectal cancer as prognostic and treatment-predictive biomarkers.